ClinicalTrials.Veeva

Menu

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Aldeyra Therapeutics logo

Aldeyra Therapeutics

Status and phase

Completed
Phase 2

Conditions

Chronic Cough

Treatments

Drug: Placebo
Drug: ADX-629

Study type

Interventional

Funder types

Industry

Identifiers

NCT05392192
ADX-629-CC-001

Details and patient eligibility

About

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough

Full description

A Phase 2, multicenter, randomized, double-blind, placebo controlled, two-period crossover trial to evaluate the safety, tolerability, and efficacy of ADX-629 (300 mg) administered orally, twice-a-day to eligible participants with refractory or unexplained chronic cough. Patients who are interested in participating will be provided detailed information about the study including description of study assessments/procedures, possible side-effects, alternative treatments, and potential benefits.

Enrollment

51 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults ≥18 to ≤80 years of age
  • History of refractory or unexplained chronic cough
  • Historical Chest radiograph or CT scan that does not demonstrate any abnormality considered to be significantly contributing to chronic cough
  • Not pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicable
  • Agree to discontinue antitussive medications for the trial duration

Exclusion criteria

  • Current smoker (including cannabis products) or previous smoker having recently given up smoking or has a history of smoking of >20 pack-years
  • History of significant cardiovascular disease or any clinically significant abnormalities in rhythm or conduction
  • History or presence of significant hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of any malignancy within 5 years of screening except for basal cell or squamous cell in situ skin carcinomas or carcinoma in situ of the cervix that has been treated with no evidence of recurrence.
  • Recent history of drug or alcohol abuse or a positive urine drug test at screening
  • Positive serology test for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or HIV-1 and HIV-2
  • Currently taking an angiotensin converting enzyme inhibitor (ACEI) or has used an ACEI within 3 months of Screening.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

51 participants in 2 patient groups, including a placebo group

ADX-629
Experimental group
Description:
Subjects will be randomized to receive ADX-629 300mg tablets administered orally twice a day for 14 days.
Treatment:
Drug: ADX-629
Placebo
Placebo Comparator group
Description:
Subjects will be randomized to receive matching placebo tablets administered orally twice a day for 14 days.
Treatment:
Drug: Placebo

Trial contacts and locations

14

Loading...

Central trial contact

BILL CAVANAGH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems